Posted on August 16, 2016 by Sitemaster
Early this morning, OncoGenex announced the result of final analysis of data from the Phase III AFFINITY trial of custirsen + cabazitaxel + prednisone in men with metastatic, castration-resistant prostate cancer (mCRPC) who had progressed after docetaxel chemotherapy. … READ MORE …
Filed under: Drugs in development | Tagged: castration-resistant, custirsen, mCRPC, metastatic, OncoGenex | Leave a comment »
Posted on June 21, 2010 by Sitemaster
OncoGenex has initiated the first of two Phase III trials of custirsen sodium (OGX-011) in the treatment of men with metastatic castrate-resistant prostate cancer (mCPRC). … READ MORE …
Filed under: Drugs in development, Uncategorized | Tagged: castration-resistant, custirsen, mCRPC, OGX-011, OncoGenex | Leave a comment »
Posted on December 22, 2009 by Sitemaster
In a somewhat surprising announcement, Teva Pharmaceuticals — best known as the world’s largest manufacturer and marketer of generic drugs — has acquired the global development and marketing rights to OGX-011 from OncoGenex. … READ MORE …
Filed under: Drugs in development | Tagged: OGX-011, OncoGenex, Teva | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 